HENGRUI PHARMA: UBS Group AG Acquires Shares, Long Position Rises to 5.23%
HK Disclosure
Sep 25
UBS Group AG bought 2.07 million shares of HENGRUI PHARMA on the SEHK open market at an average of HKD 48.8574 per share on September 21, 2026, involving about HKD 100.98 million. This was an on-exchange active trade, i.e., a direct dealing in the secondary market.
Prior to the acquisition, UBS Group AG's long position in HENGRUI PHARMA was 11.43 million shares, representing 4.43%; following the acquisition, the holding changed to 13.50 million shares, with the long position ratio rising to 5.23%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.